Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...

If you are looking to invest in top growth stocks, these companies can experience more volatility than the average stock.

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

Discussions also delved into the complexities of value-based oncology care, the growing role of real-world data, and strategies to improve access to care in hematology. Across all sessions, a common ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly already has market share in the breast cancer space with the approved drug Verzenio (abemaciclib), and is advancing investigational drugs like the oral selective estrogen receptor degrader ...

Scorpion has been collaborating with Pfizer to study STX-678 together with a so-called CDK4 inhibitor. Lilly sells a drug, called Verzenio, that similarly targets CDK4 alongside a related protein.